Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$162.20 USD

162.20
310,107

-2.02 (-1.23%)

Updated Sep 18, 2024 01:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DaVita's (DVA) Collaboration to Aid in Kidney Care Needs

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.

DaVita's (DVA) New Buyout to Enhance Transplant Experience

DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.

Trina Mukherjee headshot

Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks

With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.

New Strong Sell Stocks for December 28th

DVA, CSII, BYND, AVYA, and GFF have been added to the Zacks Rank #5 (Strong Sell) List on December 28, 2021.

DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients

DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.

New Strong Sell Stocks for November 29th

DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021

New Strong Sell Stocks for November 19th

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

New Strong Sell Stocks for November 3rd

TEAM, DVA, FLS, JD, and SBUX have been added to the Zacks Rank #5 (Strong Sell) List on November 3, 2021.

DaVita (DVA) Beats on Q3 Earnings, Narrows 2021 EPS View

DaVita's (DVA) strength in dialysis patient service revenues drives its Q3 top line.

New Strong Sell Stocks for October 29th

IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.

DaVita HealthCare (DVA) Q3 Earnings Top Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 6.79% and -0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.

DaVita HealthCare (DVA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold Onto Select Medical (SEM) Now

Select Medical (SEM) is a long-term player on the back of its leadership position in acute care services.

Why Is DaVita HealthCare (DVA) Down 2.3% Since Last Earnings Report?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sapna Bagaria headshot

Encompass Health's (EHC) Growth View Makes It a Good Buy

Ageing population, building of hospitals and other operational efforts poise Encompass Health (EHC) well for long-term growth, thus making it a good investment option.

7 Reasons Why Select Medical (SEM) Stock Looks Attractive

Select Medical (SEM) looks a profitable investment bet on the back of its top-line growth, backed by a solid financial position as well as acquisitions and joint ventures.

Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View

DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.

DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 23.36% and 1.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?

Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Pharmaceutical segment.

McKesson (MCK) to Report Q1 Earnings: What's in the Offing?

McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.